Share price heading back towards 20c - entirely predictable, post 'conviction' buying leading to window dressing day 30 June.
Meanwhile, 3 months on from the April uopdate, still not one word from KP regarding the eagerly awaited and long negotiated agreement!
Well, the field is getting more crowded with more companies providing tests (their versions will always be the best - just as PEB reckons it has the best).
Here's the latest one : https://www.insidermedia.com/insider...ncer-test-firm
Big difference is the strategies to commercialize - PEB decided to go alone and has got nowhere, judging by the $120m spent so far to get to $3.4m of revenue in FY18.
$16.2m cash as at 31 March 2018 - less accounts payable of $3m = $13.2m to cover cash burn of $1.5m to $2m a month!
4 months on so PEB must now down to about $8 to $10m in real terms.
Rights issue inevitable - expect announcement at AGM in August 2018. With the usual promises of good things around the corner!
Bookmarks